AMP presented testimony to the Patent and Trademark Office requesting moratorium on human gene patenting
Today, the Association for Molecular Pathology (AMP) asked the U.S. Patent and Trademark Office (USPTO) to place a moratorium on the issuing of patents on human genes during testimony presented at an Agency hearing on genetic diagnostic testing. AMP is the lead plaintiff of 20 plaintiffs in an American Civil Liberties Union (ACLU) sponsored lawsuit challenging the validity of patents on two hereditary breast and ovarian cancer genes, BRCA1 and BRCA2. AMP joined the litigation because of its members' first hand view of the harmful effects of gene patents on patients with genetic diseases and their at-risk family members. "Every day, AMP members witness the ability of genetic testing to better patients' lives and improve their health. Unfortunately, they also experience firsthand the challenges imposed by gene patents that interfere with the practice of medicine and limit their treatment decisions," said Mary Williams, Executive Director of AMP.